174 related articles for article (PubMed ID: 29930748)
1. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.
Loosen SH; Tacke F; Binnebosel M; Leyh C; Vucur M; Heitkamp F; Schoening W; Ulmer TF; Alizai PH; Trautwein C; Koch A; Longerich T; Roderburg C; Neumann UP; Luedde T
Oncotarget; 2018 Jun; 9(43):27027-27038. PubMed ID: 29930748
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
[TBL] [Abstract][Full Text] [Related]
3. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
[TBL] [Abstract][Full Text] [Related]
4. Circulating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver Metastases.
Loosen SH; Heise D; Dejong CH; Roy S; Tacke F; Trautwein C; Roderburg C; Luedde T; Neumann UP; Binnebösel M
J Clin Med; 2018 Oct; 7(11):. PubMed ID: 30373147
[TBL] [Abstract][Full Text] [Related]
5. Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
Loosen SH; Schulze-Hagen M; Vucur M; Gorgulho J; Paffenholz P; Benz F; Mohr R; Demir M; Wree A; Kuhl C; Trautwein C; Tacke F; Bruners P; Luedde T; Roderburg C
JGH Open; 2021 Mar; 5(3):356-363. PubMed ID: 33732882
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases.
Loosen SH; Roderburg C; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Schöler D; Paffenholz P; Tacke F; Trautwein C; Luedde T; Neumann UP; Ulmer TF
Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829346
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention.
Qin Y; Qiao Y; Wang D; Yan G; Tang C; Ma G
Int J Gen Med; 2021; 14():6497-6504. PubMed ID: 34675617
[TBL] [Abstract][Full Text] [Related]
9. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
11. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
Loosen SH; Gorgulho J; Jördens MS; Schulze-Hagen M; Beier F; Vucur M; Schneider AT; Koppe C; Mertens A; Kather JN; Tacke F; Keitel V; Brümmendorf TH; Roderburg C; Luedde T
Front Oncol; 2021; 11():646883. PubMed ID: 33869041
[TBL] [Abstract][Full Text] [Related]
12. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
Mossanen JC; Pracht J; Jansen TU; Buendgens L; Stoppe C; Goetzenich A; Struck J; Autschbach R; Marx G; Tacke F
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758975
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
[TBL] [Abstract][Full Text] [Related]
14. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
15. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.
Loosen SH; Benz F; Mohr R; Reuken PA; Wirtz TH; Junker L; Jansen C; Meyer C; Praktiknjo M; Wree A; Reißing J; Demir M; Gu W; Vucur M; Schierwagen R; Stallmach A; Kunstein A; Bode J; Trautwein C; Tacke F; Luedde T; Bruns T; Trebicka J; Roderburg C
JHEP Rep; 2024 May; 6(5):101054. PubMed ID: 38681861
[TBL] [Abstract][Full Text] [Related]
18. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
19. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
Sorio C; Mafficini A; Furlan F; Barbi S; Bonora A; Brocco G; Blasi F; Talamini G; Bassi C; Scarpa A
BMC Cancer; 2011 Oct; 11():448. PubMed ID: 21999221
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
